Large late-stage rounds and strategic institutional capital defined this week in MedTech, underscoring growing investor focus on commercialization-ready platforms, differentiated neuroscience, and clinically validated device innovation. Read more below.
Neurent raised $74M to accelerate chronic rhinitis treatment launch
MVM Partners led the Series C financing round for the company. Neurent plans to use the funds to drive commercial expansion, broaden clinical evidence and advance its product and indication pipeline.
Sofinnova Partners also provided significant participation. Existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland. In connection with the funding, MVM Partner Kyle Dempsey and Sofinnova Partner Cedric Moreau joined the company’s board.
CEO Brian Shields
Last week’s tracker: Medtronic, Reinsberg Group and more
Aerska raised a $39M Series A to treat neurological disease at the source
The new investment came just four months after the startup raised its first pool of money, making for a back-to-back fundraising that is unusual in biotech.
The round was led by EQT Dementia Fund (EQT Group) and age1, with support from Norrsken VC, and existing investors.
Co-Founder and CEO Jack O’Meara
Catheter Precision secured up to $36.5M in strategic institutional financing
The company announced that it has agreed to the termination of its at-the-market equity offering program and has completed a strategic financing transaction with institutional investors for up to $36.5M to support accelerated growth.
This investment provides the company with financial flexibility to advance key growth initiatives, scale multiple business opportunities, and expand market presence and execution capabilities.
CEO David Jenkins
Philips Seismic consortium picked up $28M for next-gen brain treatments
The consortium, coordinated by Philips with Erasmus MC as academic lead, received funding from the Innovative Health Initiative (IHI). This award aims to enable the transformation of neurosurgery.
Along with the $28M award, industry partners pledged an additional $17.7M. This includes in-kind contributions and additional resources. Altogether, this award supports a five-year research and innovation program that also includes eight clinical studies.
CEO of Philips Roy Jakobs
OncoRes Medical closed аn AUD $27M private funding round
The funding round included a cornerstone investment from Brandon Capital Partners’ BB6 Fund; significant investment from Morgans; Radar Ventures; Australian and international family offices and The Table Club network.
Proceeds will be used for clinical development and regulatory milestones for its Quantitative Micro-Elastography (QME) Imaging System, Elora.
CEO Katharine Giles
Dawn Health completed a €21.5M growth investment round
The company announced the completion of its growth investment round, following a new investment from Cipio Partners, joining the existing owner group alongside Chr. Augustinus Fabrikker (CAF), the Export and Investment Fund of Denmark (EIFO), and Trifork.
The investment builds on the growth funding provided by the company’s existing owners and will support Dawn Health’s continued expansion as an AI-enabled patient companion partner for pharma across clinical, medical, and commercial activities.
CEO Alexander Mandix Hansen
Berlin Heals raised $10M to expand its new less invasive approach
The funding, a combination of existing shareholders and new investors, will be used to advance the company’s cardiac microcurrent technology and expand its clinical research program.
The newly secured capital will support expanding indications into wider patient populations and begin larger double-blinded trials to prepare for the FDA IDE submission.
CEO John Brumfield
iGan Partners led a $10M financing of Exact Imaging
Proceeds from the financing will be used to accelerate global sales and adoption of the Company’s flagship ExactVu™ prostate biopsy system.
With the strength of the company’s clinical evidence and growing global demand, this capital allows to scale its commercial footprint worldwide and bring ExactVu to many more urologists and patients.
CEO Randy AuCoin
NuVision Biotherapies raised £4.8M to boost overseas expansion
The funding round was led by the Midlands Engine Investment Fund II through its appointed fund manager Mercia Ventures, and including the University of Nottingham and Pioneer Group.
The funding will help the Nottingham-based company to meet growing demand by scaling up the business and enter more international markets.
Founder Andrew Hopkinson
Curapod raised $2.2M to expand wearable pain management devices
Curapod by Litemed India raised $2.2M (INR 20 Cr) in a pre-Series A funding round led by V3 Ventures, 3i Partners and Ideaspring Capital, as it looks to scale its FDA-registered wearable devices for non-invasive musculoskeletal pain management.
The funding will support research and development, device and app enhancements, manufacturing scale-up, and broader go-to-market execution.
Co-Founder and CEOSri Velliyur
